AristaCare at Whiting: OxyContin Delays Repeated - NJ
Inspectors responding to a complaint documented 13 separate occasions between January and May 2025 when the facility administered OxyContin ER past its prescribed window. The medication is an extended-release formulation of oxycodone, a powerful opioid prescribed on a schedule precisely because consistent timing is how the drug works. Extended-release opioids are designed to maintain steady levels in the bloodstream. When doses arrive late, that steadiness breaks down.
The pattern began on New Year's Day. A dose due at 9 p.m. on January 2 wasn't given until 10:52 p.m., nearly two hours later. Three days after that, a 9 a.m. dose waited until 10:25 a.m. The delays continued without interruption across the rest of the month: January 5, January 6, January 7, January 8, January 10, January 11, January 13, January 15, January 18 morning, January 18 evening. On January 13, the 9 p.m. dose didn't arrive until 11:39 p.m., a gap of two hours and 39 minutes. Then, months later, on May 2, a noon dose wasn't given until 2:55 p.m.
That is nearly three hours.
The facility's own written policy, titled "Administering Medications," states that medications must be administered within one hour of their prescribed time. The same policy prohibits preparing medications in advance. Inspectors reviewed it. The policy existed. The delays happened anyway, repeatedly, over the course of four and a half months.
The inspection was classified as a complaint survey, meaning someone raised a concern that triggered the visit. The level of harm was recorded as minimal harm or potential for actual harm, and the number of residents affected was listed as few.
What the record does not contain is any explanation from staff or administrators about why the same medication, for the same resident or residents, ran late on thirteen separate occasions without the pattern being corrected. The first delay was January 2. The last documented delay was May 2. Whatever internal process should have caught this after the second or third late dose did not catch it, or did not change anything if it did.
Extended-release OxyContin is not a medication with much tolerance for inconsistency. It is prescribed to people in significant, ongoing pain, typically because shorter-acting options aren't providing adequate relief across the day. The whole clinical logic of the formulation is that the drug releases gradually over twelve hours, maintaining a therapeutic level that keeps pain controlled without the spikes and crashes of immediate-release opioids. A dose that arrives two hours late doesn't just mean two hours of waiting. It means the prior dose's coverage has already worn thin, and the gap is filled with whatever the resident experiences when their pain medication isn't working.
The inspection covered three pages. The medication timing violations filled most of them.
AristaCare at Whiting is a nursing and rehabilitation facility in Ocean County. The August 14 inspection was a complaint survey, not a routine annual review. Someone, at some point before August, decided what was happening was worth reporting.
The timestamps in the inspection report are precise and numerous. 9:00 a.m. due, 10:07 a.m. given. 9:00 p.m. due, 10:03 p.m. given. 9:00 a.m. due, 11:09 a.m. given. Thirteen entries, each one a scheduled moment that passed without the medication being delivered on time. The facility's own policy set the one-hour limit. Inspectors found the limit was exceeded every single time.
What happened to the resident, or residents, during those gaps is not in the inspection report. The clinical consequences, the pain levels, the nights spent waiting, none of that is documented in what surveyors recorded. What is documented is the clock. Due at nine. Given at eleven-thirty-nine.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Aristacare At Whiting from 2025-08-14 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: This article is based on inspection data downloaded directly from the Centers for Medicare & Medicaid Services (CMS) via Medicare.gov. CMS releases inspection reports in bulk; we publish the findings as documented by state surveyors in the official Form CMS-2567 Statement of Deficiencies.
Plan of correction: The CMS report we receive does not include the facility's plan of correction. Facilities submit plans of correction separately to state survey agencies and those responses may not be reflected in CMS data at the time of publication. The absence of a plan of correction in our data does not mean one was not filed. Readers who want information about corrective steps taken are encouraged to contact the facility directly or their state survey agency.
Corrections may have occurred: Inspection reports reflect conditions observed on the date of the survey. Facilities may have implemented corrections, staffing changes, additional training, or other remediation since the report was issued. We report what CMS provides and encourage readers to seek current information from the facility.
Editorial process: Inspection findings are extracted from CMS source documents and synthesized using AI, reviewed for factual accuracy against the original report by our editorial team.
Corrections: We strive for accuracy in everything we publish. If you believe any fact in this article is incorrect, please contact us with details, and we will review and correct it promptly.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: October 20, 2026 · Our methodology
ARISTACARE AT WHITING in WHITING, NJ was cited for violations during a health inspection on August 14, 2025.
Extended-release opioids are designed to maintain steady levels in the bloodstream.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.